Atrial Fibrillation Perspective

 
 

  • Mandrola Previews (Virtual) ACC 2021 Presentations on aspirin dosing, surgical left atrial appendage occlusion, heart failure rehab, and rate vs rhythm control are among the top picks from the virtual ACC 2021, according to John Mandrola, MD.
  • ACC 2021 Read clinically focused news coverage of key developments from ACC 2021
  • Apr 30 2021 This Week in Cardiology   COVID-19 and global vaccinations, AF screening, conduction-system pacing, FDA ban on menthol tobacco, and a heartfelt essay are the topics John Mandrola, MD, discusses in this week’s podcast.
  • Apr 23 2021 This Week in Cardiology   Cardiac status post COVID-19 in athletes, AF ablation, and bias against procedural doctors are the topics covered by John Mandrola, MD, in this week’s podcast.
  • ECG Challenge: What Triggered AF Patient's Shortness of Breath? A patient with atrial fibrillation visits the emergency department with lightheadedness and shortness of breath. What clues can be found in his ECG?
  • Can Minimally Invasive SAVR Challenge TAVR?   Cardiologist Wayne Batchelor talks with cardiothoracic surgeon Tom Nguyen about his experience with minimally invasive aortic valve replacement surgery.
  • Apr 9 2021 This Week in Cardiology   COVID-19, COVID-19 vaccines, hybrid AF ablation, TAVR, and who gets to be called a doctor are the topics covered by John Mandrola, MD, in this week’s podcast.
  • Cardiac Rehabilitation and Implications in the COVID-19 Era As the COVID-19 pandemic continues, the integration of a home-based rehabilitation program is imperative to improve the delivery of care, patient safety and cardiovascular outcomes.
  • Mar 26 2021 This Week in Cardiology   COVID-19, AF detection post stroke, new measures of heart function, and structural racism in quality measures are the topics covered by John Mandrola, MD, in this week’s podcast.
  • Mar 19 2021 This Week in Cardiology   COVID-19, Fish Oil and AF risk, SGLT2 inhibitors and renal outcomes, and TAVR vs SAVR are the topics discussed by John Mandrola, MD, in this week’s podcast.
  • March 12 2021 This Week in Cardiology   COVID-19, heart failure classifications, DOAC after bioprosthetic valves, and Medicare spending in the pandemic year Are the topics discussed by John Mandrola, MD, in this week’s podcast.
  • Feb 5 2021 This Week in Cardiology   Carotid screening, AF and alcohol, subcutaneous ICD, and medical education are the topics discussed by John Mandrola, MD, in this week’s podcast.
  • Jan 29 2021 This Week in Cardiology   AF and COVID-19, microthrombi in COVID-19 autopsies, vericiguat, and POTS are the topics covered by John Mandrola, MD, in this week’s podcast.
  • Antiplatelet Therapy: Where Do We Stand Now?   Can duration of DAPT be shortened? Is single antiplatelet therapy an option? Drs Bangalore and Baber discuss these topics in antiplatelet therapy and more.
  • ECG Challenge: Did COPD Cause This Man's Irregular Heart Rate? A middle-aged COPD patient is intubated after experiencing respiratory distress and is found to have an irregular heartbeat. What does his ECG show?
  • Jan 15 2021 This Week in Cardiology   COVID, ACE/ARBs, left atrial appendage closure, SGLT2 inhibitors, and a clue in AF mechanisms are the topics discussed by John Mandrola, MD, in this week’s podcast.
  • Highlights in Mantle Cell Lymphoma From ASH 2020   Dr Amanda Cashen from Washington University reviews key studies on mantle cell lymphoma from ASH 2020, including new data on chemotherapy-free frontline options and CAR T-cell therapy.
  • Mandrola's Top 10 in Cardiology for 2020 While the pandemic dominated the medical news, there were both exciting and concerning developments in the world of cardiology.
  • Dec 11 2020 This Week in Cardiology   COVID, the clogged pipe frame of CAD, paclitaxel, and AF performance measures and Goodhart’s law are the topics John Mandrola, MD, covers in this week’s podcast.
  • Fish Oils and CV Prevention -- Now What?   Drs Tracy Wang and Renate Schnabel discuss new data on omega-3 fatty acids from the REDUCE-IT trial of icosapent ethyl. Do the STRENGTH, OMEMI, and VITAL Rhythm trials from the AHA meeting raise concerns?